Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.31 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25875905 | 0.90 | KLKB1 (0.31) | DGAT1KLKB1 | |
| SCHEMBL25875942 | 0.85 | MAT2A (0.42) | MAT2APDE4B | |
| SCHEMBL25876041 | 0.85 | MAT2A (0.35) | MAT2AHSP90AA1HSP90B1TRAP1PDE4A | |
| SCHEMBL25876077 | 0.84 | MERTK (0.35) | MAT2AHSP90AA1HSP90B1TRAP1PDE4A | |
| SCHEMBL25876233 | 0.84 | MAT2A (0.33) | MAT2AHSP90AA1HSP90B1TRAP1PDE4A | |
| SCHEMBL25876275 | 0.84 | PDE1A (0.36) | MAT2AHSP90AA1HSP90B1TRAP1PDE4A | |
| SCHEMBL25876299 | 0.82 | LRRK2 (0.36) | MAT2AHSP90AA1HSP90B1TRAP1PDE4A | |
| SCHEMBL25875993 | 0.82 | MAT2A (0.33) | MAT2AHSP90AA1HSP90B1TRAP1PDE4A | |
| SCHEMBL25875863 | 0.80 | PDE2A (0.41) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25876131 | 0.80 | PDE9A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | DGAT1 4284/4885MAT2A 686/4885KLKB1 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.